

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 August 2025 (28.08.2025)



(10) International Publication Number
WO 2025/179128 A1

(51) International Patent Classification:

A61K 31/472 (2006.01) A61P 25/22 (2006.01)
A61P 25/08 (2006.01) A61P 25/24 (2006.01)

(21) International Application Number:

PCT/US2025/016769

(22) International Filing Date:

21 February 2025 (21.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/556,681 22 February 2024 (22.02.2024) US

(71) Applicant: **XENON PHARMACEUTICALS INC.**
[CA/CA]; 3650 Gilmore Way, Burnaby, BC V5G 4W8
(CA).

(72) Inventors: **FORGACS, Peter, Bertalan**; C/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8 (CA). **BEATCH, Gregory, N.**; C/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8 (CA). **BUTTERFIELD, Noam, Douglas Nahum**; C/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8 (CA). **DHAKAR, Monica, Bhagwansingh**; C/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8 (CA). **GRAYSON, Celene**; C/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8 (CA). **NAMDARI, Rostam**; C/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8 (CA). **ODINECS, Aleksandrs**; C/o Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, BC V5G 4W8 (CA).

(74) Agent: **SAMBLANET, Danielle, C.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: AZETUKALNER FOR USE IN THE TREATMENT OF DEPRESSION, ANHEDONIA OR A SEIZURE DISORDER SUCH AS EPILEPSY IN PEDIATRIC SUBJECTS

(57) Abstract: In certain embodiments, the present disclosure is directed to methods for treating disorders, including depressive disorders, seizure disorders, and anhedonia, in a pediatric subject, wherein the methods comprise orally administering a therapeutically effective amount of the voltage-gated potassium channel allosteric modulator, A-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (azetukalner), or a pharmaceutically acceptable salt thereof, to the pediatric subject, for example, under fed conditions.

WO 2025/179128 A1